Business
Anavex is a clinical-stage biopharma focused on precision medicine for central nervous system diseases.
Anavex remained pre-revenue, losses widened, cash use rose, and there was no insider activity in the local window.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage CNS drug developerNote
- Revenue — No FY2025 revenueNote
- Losses — Net loss widened to $46.4MWatch
- Cash — Cash from ops worsened to -$39.0MWatch
- Balance sheet — Equity fell 21.1%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailableNote
Leadership changes
From ANAVEX LIFE SCIENCES CORP.'s own filings, the day they're filed.
- Felix Lauscher · Chief Operating Officer · departureeff. 2026-05-11
- Terrie Kellmeyer · Chief Executive Officer · appointmenteff. 2026-05-04
- Axel Paeger · directors · appointmenteff. 2026-02-23
Latest filings
- 8-K · Company announcement2026-09-02
- 10-Q · Quarterly report2026-08-28
- 10-Q · Quarterly report2026-08-28
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ANAVEX LIFE SCIENCES CORP., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.